Yazılar

Abercrombie & Fitch Reports 21% Sales Growth and Raises Outlook Despite Economic Uncertainty

/in /tarafından

Abercrombie & Fitch has reported a substantial 21% increase in revenue for its fiscal second quarter, building on a 16% sales growth from the same period last year. This robust performance has led the apparel retailer to provide optimistic guidance for the current quarter, though its full-year forecast aligns with expectations due to the impact of having one fewer week in the fiscal year.

CEO Fran Horowitz acknowledged the “increasingly uncertain environment” for the first time in four quarters but expressed confidence in the company’s ability to maintain strong performance. She emphasized the company’s commitment to sustainable, profitable growth while continuing to invest strategically in marketing, digital technology, and store expansions.

Despite the positive earnings report, Abercrombie’s shares experienced a 9% drop in premarket trading. The company reported earnings per share (EPS) of $2.50, exceeding the expected $2.22, and revenue of $1.13 billion, surpassing the anticipated $1.10 billion. Net income for the quarter ending August 3 rose to $133 million from $57 million a year earlier.

Same-store sales increased by 18%, driven by strong summer and back-to-school performance. For the current quarter, Abercrombie forecasts a low double-digit percentage increase in sales, outperforming the 8.9% growth expected by analysts. The company has raised its full-year sales growth forecast to 12-13%, in line with analyst predictions, though the loss of one selling week is expected to impact sales by $80 million in the holiday quarter and $50 million for the full year.

Abercrombie has emerged as a notable success story in retail, with notable sales growth at its Hollister and Abercrombie Kids brands. Sales at Hollister rose 17%, and comparable sales increased by 15%, while the Europe, Middle East, and Africa division saw a 16% boost. The company is also expanding internationally, having recently partnered with Haddad Brands to broaden Abercrombie Kids’ distribution and product offerings.

 

Novo Nordisk Shares Dip Amid Earnings Miss and Reduced Profit Outlook

/in /tarafından

Novo Nordisk experienced a dip in its share price after posting weaker-than-expected net profit for the second quarter and revising its operating profit outlook downwards. The pharmaceutical giant reported a net profit of 20.05 billion Danish kroner ($2.93 billion) for the quarter ending in June, falling short of the 20.9 billion Danish kroner projected by LSEG analysts. Additionally, the company’s EBIT (earnings before interest and tax) was 25.93 billion Danish kroner, below the forecasted 26.86 billion Danish kroner.

In response to these results, Novo Nordisk adjusted its full-year 2024 operating profit growth expectations to a range of 20% to 28%, down from the previous 22% to 30%. This announcement caused the company’s shares to tumble nearly 7% before recovering slightly, trading down 2.71% by 9:40 a.m. London time.

Despite the disappointing second-quarter earnings, Novo Nordisk raised its sales growth guidance for the full year, expecting growth between 22% and 28% at constant exchange rates, up from the previous estimate of 19% to 27%. This optimism is partly driven by a 55% increase in sales of its popular weight loss drug, Wegovy, which reached 11.66 billion kroner in the second quarter compared to the same period in 2023.

CEO Lars Fruergaard Jørgensen expressed confidence in the company’s future growth, highlighting the potential for “attractive growth” in the coming months. He assured investors of the company’s ability to scale operations and supply patients, emphasizing that adjustments to rebates were a factor in the second-quarter results. Jørgensen remains positive about the long-term competitiveness of Novo Nordisk, even in the face of increasing competition from companies like Roche, which recently reported promising early-stage trial data for its obesity drug candidate.

Moreover, Novo Nordisk’s Wegovy has recently achieved significant milestones. The drug was approved for sale in China, the world’s second-largest economy, and received backing from medical regulators in the U.K. and European Union for reducing risks of serious heart events among overweight and obese adults.